Dec. 27, 2028-- Horizon Pharma plc(NASDAQ: HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to expand the age range for RAVICTI? (gl……
- The first I-Mab proprietary drug candidate to enter clinical trials in the United StatesI-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development o……
September 28, 2028 The US Food and Drug Administration (FDA) has banned imports of active pharmaceutical ingredients (API) and finished drug products produced by China's Zhejiang Huahai Pharmaceuticals……
On Nov.29th, The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects ……
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx? (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previou……
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA? (product name in China: 樂(lè )衛瑪?, generic nam……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
